Solution of the antitumor effect and clinical trials of the peptide vaccine therapy for renal cel carcinoma and bladder cancer

我们利用临床标本调查了与多肽疫苗治疗效果相关的预测因素。所有病例均有MPHOSPH1和DEPDC1抗原的表达，但表达强度与肿瘤的分级和分期无关。8例接种后出现CTL诱导，且在随访期内仍维持CTL诱导。与缺席的病例相比，认识到疫苗接种部位的反应的患者复发率降低。表现状态、CTL诱导和注射部位反应被确定为多肽疫苗治疗的相关因素。

We investigated the predictive factor associated with the effect of the peptide vaccine treatment using clinical specimen. The expression of MPHOSPH1 and DEPDC1 antigen were recognized in all cases, but there was no correlation between expression intensity and grade and stage of the tumor. Cases 80% or more showed CTL induction after vaccination, and the CTL induction was maintained during follow-up period. The patient in recognition of the response of the vaccine administration site showed a decrease of the recurrence rate as compared with an absent case. Performance Status, CTL induction and injection site reaction were identified as an associated factor of the peptide vaccine treatment.